June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Low Neighborhood SES Linked to Higher HS Risk: Study 

A large cross-sectional study of over 65,000 dermatology patients found that individuals living in lower socioeconomic neighborhoods had significantly higher odds of receiving a new diagnosis of hidradenitis suppurativa, with risk decreasing across increasing SES levels.

Conexiant

May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant

May 23, 2025

Patients With Psoriasis Show Inflammation Despite Skin Clearance

Over one-third of psoriasis patients had elevated hs-CRP despite biologic treatment and skin clearance, with obesity, female sex, and fatty liver disease identified as key predictors of residual inflammation.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 19, 2025

Phase 3 Data Backs Roflumilast Foam

Roflumilast foam was found to improve scalp and body psoriasis symptoms with favorable tolerability in patients aged 12 years and older.

Conexiant

April 30, 2024

Novel Gene Variants May Be Predisposing Factor for Generalized Pustular Psoriasis

Researchers may have uncovered genetic factors linked to the development of generalized pustular psoriasis.

Conexiant

November 26, 2024

PsA Clusters Identified for Tailored Treatment: Longitudinal Study

A recent study reveals significant treatment response improvements in severe psoriatic arthritis and extensive psoriasis, emphasizing the need for personalized treatment strategies and sensitive outcome measures. (Source: Psoriatic Arthritis Research Consortium)

Conexiant